Month: April 2014

Draining fluid can counter large choroidal detachments

BOSTON — When dealing with large choroidal detachments, draining the choroidal fluid is a simple, low-risk way to stabilize the eye, a speaker here said. “Drainage of choroidal fluid will definitely re-establish the anatomy of the eye,” Marlene R. Moster, MD, told attendees at Glaucoma Day preceding the American Society of Cataract and Refractive Surgery annual meeting. “It will preserve the bleb as aqueous formation will resume almost immediately to restore good vision, all with the minimal trauma of a 3-mm incision.”

New manual trabeculotome may improve outcomes for ab interno trabeculotomy

BOSTON — A new single-handed trabeculotome, the Trab 360, can manually cut up to 360° of meshwork through a single corneal incision, a speaker here said. “The entire trabecular meshwork is removed from the eye; nothing is left behind. There’s often some microscopic bleeding associated with this, which may remain there for a week or so,” John A. Hovanesian, MD, FACS, told attendees during Glaucoma Day preceding the American Society of Cataract and Refractive Surgery annual meeting. “The instrument has been used as a standalone and combined with phacoemulsification in (Read more...)

Speaker describes new device for measuring corneal biomechanical strength

BOSTON — Avedro is developing a new initiative, Brillouin spectroscopy, which would enable surgeons to create a 3-D strength map of the cornea, a speaker here said. “What we want this for is treatment planning for corneal collagen cross-linking,” David Muller, PhD, president and CEO of Avedro, told attendees at the Ophthalmology Innovation Summit. “It’s built to take information from other mapping systems, combine them and filter them through a computational engine to pump out a map that a surgeon can use to assess an eye’s corneal biomechanical strength.” Muller (Read more...)

Speaker describes nanostructured sustained-release drug delivery system

BOSTON — A new device in development for the sustained release of ocular therapies is nanostructured to optimize drug delivery, is completely bioerodible and can be administered intraocularly intramuscularly or subcutaneously, a speaker here said. Focusing on long-term sustained delivery, the delivery system, called Tethadur, is designed for the release of large molecules, including antibodies to the eye, according to Paul Ashton, president and CEO of pSivida.

Early critique of projects can help determine viability, increase potential for success

BOSTON — Being critical of a project or venture early in the innovation cycle is crucial to determining its success, according to a panel here. “Having an incubator team is really great,” K. Angela Macfarlane, president and CEO of ForSight Labs, said during a panel discussion concerning the innovation cycle at the Ophthalmology Innovation Summit. “Someone arguing for a project one day, against it the next. It forces you to look candidly at a project’s merits and how they measure up in clinic, against the competition, in the current marketplace. (Read more...)

Private ophthalmic companies showcase innovative new IOLs

BOSTON — At the Ophthalmology Innovation Summit here, officials from several ophthalmic companies touted innovative new products currently under development. Anew Optics is developing the Zephyr, an IOL design based on maintaining an open capsule and allowing circulation of the aqueous humor, according to CEO Anna Hayes. The Zephyr is an 8.8-mm fully circular lens that keeps the capsule open and impedes lens epithelial migration, and the posterior ring keeps the optical zone clear, Hayes said.

New law will modernize Medicare lab payments: What physicians need to know

Medicare will make sweeping changes in how it pays for clinical laboratory tests starting in 2017. The Protecting Access to Medicare Act, enacted April 1, will make the most significant reform of Medicare’s Clinical Laboratory Fee Schedule (CLFS) since its introduction in 1984, by setting CLFS payment amounts based on rates paid for laboratory tests in the private sector.Medicare’s payment amounts for pathology laboratory services paid under Medicare’s physician fee schedule (PFS) will be unchanged by the new law. Also unchanged will be Medicare’s policy of not imposing coinsurance on (Read more...)